Autolus Therapeutics Plc's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Autolus Therapeutics Plc's ROA in the second quarter of 2026?
Autolus Therapeutics Plc recorded a cumulative net loss of $-280 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -49.38%.

However, within the Healthcare sector 560 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3884, from total ROA ranking in the first quarter of 2026 at 4489.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-31.59 %	-29.38 %	-33.28 %	-13.4 %	-10.35 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-280	-289	-288	-225	-228
Return On Assets (TTM)	-49.38 %	-46.29 %	-42.34 %	-29.88 %	-29.28 %
AUTL's Total Ranking	# 3884	# 4489	# 3785	# 3777	# 3844
Total Assets (TTM) in million	493	527	587	662	721
Seq. Total Assets Change	-6.42 %	-10.22 %	-11.31 %	-8.19 %	-3.4 %
Seq. Net Income Change	-	-	-	-	-

AUTL's 5 Years Annual ROA >> Back to AUTL Management Effectiveness >> Compare AUTL ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 78
Sector	# 561
Overall	# 3884

Return On Assets Statistics
High	Average	Low
-26.23 %	-39.87 %	-61.98 %
(Dec 31 2024)		(Sep 30 2023)

Financial Statements
Autolus Therapeutics Plc's Assets	$ 493 million	AUTL's Balance sheet
Autolus Therapeutics Plc's Income	$ -39 million	Quarterly AUTL's Income Statement
AUTL's Income by Division		See AUTL's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-33.28 %	102.65 %	-22.43 %	19.9 %	63.03 %
Total Assets in million	587	880	434	560	467
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-288	-221	-208	-149	-142
Annual Return On Assets	-48.98 %	-25.08 %	-47.99 %	-26.59 %	-30.44 %

AUTL's 5 Years Annual ROA >> Back to AUTL Management Effectiveness >> Compare AUTL ROA to its Competitors

More Return On Assets Ratios
AUTL's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
AUTL's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for AUTL's Competitors
Subscribers only: Roa for Autolus Therapeutics Plc's Suppliers
Subscribers only: Return On Assets for AUTL's Customers

You may also want to know
AUTL's Roi	AUTL's Inventory Turnover Ratio	AUTL's Growth Rates	AUTL's Dividend Comparisons
	AUTL's Profitability Ratios	AUTL's Asset Turnover Ratio	AUTL's Dividend Growth
AUTL's Roe	AUTL's Valuation Ratios	AUTL's Financial Strength Ratios	AUTL's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-12T06:24:39+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.